• Researcher Profile

    Kimberly Stegmaier, MD

     
    Kimberly Stegmaier, MD
     
    Co-Director of the Pediatric Hematologic Malignancy Program
    Physician
    Ted Williams Chair


    Associate Professor of Pediatrics, Harvard Medical School

    Center/Program

    Pediatric Hematologic Malignancies

    Office phone: 617-632-4985
    Fax: 617-632-4850
    Email: kimberly_stegmaier@dfci.harvard.edu

    Preferred contact method: email

    View Physician Profile
     
     

    Research Department

    Pediatric Oncology

    Interests

    Chemical screening, Neuroblastoma, Ewing Sarcoma, Hematologic malignancies, Cancer genomics

    Area of Research

    Principal Investigator


    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana 630D
    Boston, MA 02215

    Biography

    Kimberly Stegmaier, M.D., is an Associate Professor of Pediatrics at Harvard Medical School, a Principal Investigator in Pediatric Oncology at the Dana-Farber Cancer Institute (DFCI), and anAttending Physician at the Boston Children’s Hospital Boston (BCH) and DFCI. She is the Co-director of the Pediatric Hematologic Malignancies Program at DFCI and BCH and is also an Associate Member of the Broad Institute of Harvard and MIT. She received her B.S. from Duke University and her M.D. from Harvard Medical School. She completed her residency at BCH and a post-doctoral pediatric hematology-oncology fellowship at DFCI/BCH. In 2006, she launched her own laboratory effort at DFCI.

    Dr. Stegmaier’s laboratory integrates chemical biology, genomic, and proteomic approaches to discover new lead compounds and protein targets for cancer therapy. She has focused her efforts on the acute leukemias and two pediatric solid tumors of childhood: Ewing sarcoma and neuroblastoma.

    Recent Awards

    • Clifford Barger Excellence in Mentoring Award, Harvard Medical School, 2014
    • Osler Young Investigator Award, Interurban Clinical Club, 2013
    • Society for Pediatric Research (SPR) Young Investigator Award, 2012
    • Stephen E. Sallan Leadership Award, 2012
    • American Society for Clinical Investigation, Elected Member, 2009
    • SU2C Innovative Research Grant Recipient, 2009
    • Genome Technology “Tomorrow’s Principal Investigator” Award, 2007
    • Joanne Levy, MD, Memorial Award for Outstanding Achievement, American Society of  Hematology, 2006

    Research

    Principal Investigator


    My research program focuses on the integration of “omic” approaches for the identification of new protein targets and small-molecule modulators of malignancy with an eye toward clinical translation. Cancer discovery efforts in my laboratory have focused on the alteration of the malignant state (e.g., AML and neuroblastoma differentiation) and the modulation of pharmacologically challenging oncoproteins (e.g., EWS/FLI in Ewing sarcoma, MYCN in neuroblastoma, and NOTCH1 in T-ALL.) Most recently, we are applying an integrated approach to discover new therapeutic opportunities in these malignancies with deep genomic characterization of primary tumors, kinase activity profiling for immediately druggable targets, functional genomic screening for new tumor dependencies and chemical screening for modulators of relevant oncogenic drivers. Clinical trials for patients with AML and Ewing sarcoma have resulted from our research and a trial testing BET bromodomain inhibitors in patients with MYCN amplified neuroblastoma is in development.


     

    Trainees

    • Crompton, Brian, MD
    • Roti, Giovanni, MD, Ph.D.
    • Banerji, Versha, MD, FRCP(c)
    • Pikman, Yana, M.D.
    • Puissant, Alexandre, Ph.D.
    • Chen, Liying, Ph.D.
    • Thorner, Aaron, Ph.D.
    • Carnevale, Julia, HHMI Fellow, HMS Medical Student
    • Li, Puyao C., HST/MIT-Harvard Student
    • Vallurupalli, Mounica, HHMI Fellow, HMS Medical Student
    • Patel, Sarvagna, HST Harvard/MIT Student
View Physician Directory

Find a Clinical Trial

Support Cancer
Research

Give Now